Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial

Table 1

Comparison of clinical data.

Items	SG (n = 37)	RG (n = 37)	χ^2/t
Gender			0.492	0.483
Male	22 (59.46%)	19 (51.35%)
Female	15 (40.54%)	18 (48.65%)
Average age (years old)	53.21 ± 6.51	53.25 ± 6.38	0.027	0.979
Average BMI (kg/m^2)	22.84 ± 1.73	22.86 ± 1.78	0.049	0.961
Pathological staging			0.237	0.626
III	23 (62.16%)	25 (67.57%)
IV	14 (37.84%)	12 (32.43%)
Pathological types
Poorly differentiated adenocarcinoma	16 (43.24%)	14 (37.84%)	1.458	0.227
Medium differentiated adenocarcinoma	17 (45.95%)	18 (48.65%)	0.046	0.831
Carcinoma mucocellulare	4 (10.81%)	5 (13.51%)	0.127	0.722
Organ metastasis types			0.237	0.626
Single organ metastasis	14 (37.84%)	12 (32.43%)
Multiple organ metastasis	23 (62.16%)	25 (67.57%)
Residence			0.218	0.641
Urban area	19 (51.35%)	21 (56.76%)
Rural area	18 (48.65%)	16 (43.24%)